Oct282019UncategorizedCategory: UncategorizedBy Charlotte Maddalena28 October 2019 Author: Charlotte Maddalena Post navigationPreviousPrevious post:ORPHELIA announces the appointment of Dr. Caroline Lemarchand as Chief Pharmaceutical Development OfficerNextNext post:Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapiesRelated PostsOREGA Biotech enters into a License Agreement with Genmab6 December 2022Newsletter December 20222 December 2022Publication: dispensing temozolomide using KIMOZO or Temodal capsules mixed with food30 September 2022SIOP 2022, Barcelona, Spain: September 28-October 1, 202223 September 2022Organisation Inter Régionale Hémato-Onco pédiatrique14 September 2022Five new projects supported by our Foundation5 July 2022
Publication: dispensing temozolomide using KIMOZO or Temodal capsules mixed with food30 September 2022
